IgA肾病的治疗进展

摘要

Immunoglobulin A ( IgA ) nephropathy is the most common primary glomerular disease. Since the pathogenesis of it is not identified yet,there is still no specific drugs for the treatment. It was considered that the progress of IgA nephropathy was slow and eusemia, but now it is discovered that it is not a benign lesion. 15 ％～40％ of IgA nephropathy will develop into the end stage renal disease. Currently the major objective in clinical treatment is to reduce proteinuria,control blood pressure and/or high uric acid and decrease the further injuries of the kidney, keeping renal function stable.%IgA肾病是最常见的原发性肾小球疾病,由于其发病机制尚未明确,目前仍无特异性治疗药物.早期认为IgA肾病进展缓慢,预后良好.但近年研究发现IgA肾病并非一种良性病变,15%～40%的IgA肾病患者在15年后会进展成终末肾衰竭.目前临床上的治疗目标是有效降低蛋白尿、控制血压和(或)高尿酸并减少肾组织进一步损伤,维持肾功能稳定为主.